Opera Ltd (OPRA) Q1 2021 Earnings Call Transcript Motley Fool Transcribers © The Motley Fool Logo of jester cap with thought bubble.
Opera Ltd (NASDAQ: OPRA)
Operator
Welcome to the Opera Limited First Quarter 2021 Earnings Call. [Operator Instructions] I would now like to turn the call over to your speaker today, Derrick Nueman, Head of Investor Relations. Please begin.SPONSORED:
10 stocks we like better than Opera Ltd
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade,
Motley Fool Stock Advisor, has tripled the market.
Dolphin Entertainment Salutes 42West And Shore Fire Media On Their Success At The Academy Awards
tennesseedaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tennesseedaily.com Daily Mail and Mail on Sunday newspapers.
Opera Ltd (OPRA) Q1 2021 Earnings Call Transcript
fool.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from fool.com Daily Mail and Mail on Sunday newspapers.
Share this article
Share this article
TEL-AVIV, Israel, April 26, 2021 /PRNewswire/ Chemomab Therapeutics, Ltd. (Nasdaq: CMMB), a clinical-stage biotech company focused on the discovery and development of innovative therapeutics for fibrosis-related diseases with high unmet need, today announced enrollment of the first patient in its Phase 2a study of CM-101 in Non-Alcoholic Steatohepatitis (NASH). CM-101 is a first-in-class humanized monoclonal antibody designed to bind to and block CCL24 activity, an important chemokine activity that stimulates inflammation and the development of fibrosis.
The Phase 2a study is a multi-center, randomized, double-blind, placebo-controlled, multiple dose study designed to assess the mechanism of action, safety, pharmacokinetics and pharmacodynamic effects, as well as the anti-fibrotic effects of subcutaneous CM-101 in NASH patients with fibrosis stage F2-F3. The trial will enroll 40 patients and is anticipated to complete enrollment by the end
Share this article
Share this article
BETHESDA, Md., April 26, 2021 /PRNewswire/ AGNC Investment Corp. ( AGNC or the Company ) (Nasdaq: AGNC) today announced financial results for the quarter ended March 31, 2021.
FIRST QUARTER 2021 FINANCIAL HIGHLIGHTS
$1.33 comprehensive income per common share, comprised of:
$1.77 net income per common share
$(0.44) other comprehensive loss ( OCI ) per common share on investments marked-to-market through OCI
$0.76 net spread and dollar roll income per common share, excluding estimated catch-up premium amortization benefit
1
Includes $0.29 per common share of dollar roll income associated with the Company s $32.0 billion average net long position in forward purchases and sales of Agency mortgage-backed securities ( MBS ) in the to-be-announced ( TBA ) market